TEVA-TERIPARATIDE INJECTION SOLUTION

Country: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

TERIPARATIDE (TERIPARATIDE ACETATE)

Disponibbli minn:

TEVA CANADA LIMITED

Kodiċi ATC:

H05AA02

INN (Isem Internazzjonali):

TERIPARATIDE

Dożaġġ:

250MCG

Għamla farmaċewtika:

SOLUTION

Kompożizzjoni:

TERIPARATIDE (TERIPARATIDE ACETATE) 250MCG

Rotta amministrattiva:

SUBCUTANEOUS

Unitajiet fil-pakkett:

15G/50G

Tip ta 'preskrizzjoni:

Prescription

Żona terapewtika:

PARATHYROID AGENTS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0150152001; AHFS:

L-istatus ta 'awtorizzazzjoni:

APPROVED

Data ta 'l-awtorizzazzjoni:

2019-08-06

Karatteristiċi tal-prodott

_Teva-Teriparatide Injection _
_Page 1 of 61_
PRODUCT MONOGRAPH
PR
TEVA-TERIPARATIDE INJECTION
Sterile Solution for Subcutaneous Injection
250 mcg / mL teriparatide (as teriparatide acetate)
Teva Standard
Bone Formation Agent
Teva Canada Limited
30 Novopharm Court
Toronto, ON M1B 2K9
Date of Revision:
April 17, 2023
Submission Control No: 269436
_Teva-Teriparatide _
_Page 2 of 61 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
DESCRIPTION....................................................................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
....................................................................................................8
DRUG INTERACTIONS
..................................................................................................12
DOSAGE AND ADMINISTRATION
..............................................................................13
OVERDOSAGE
................................................................................................................14
ACTION AND CLINICAL PHARMACOLOGY
............................................................14
STORAGE AND STABILITY
..........................................................................................18
INSTRUCTIONS FOR PEN USE
.....................................................................................19
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................19
PART II: SCIENTIFIC INFORMATION
.............................................................